Braveheart Bio, Inc. (BRVE) vs Zymeworks Inc. (ZYME)
- Braveheart Bio, Inc. BRVE 19.62 −4.29%
- Zymeworks Inc. ZYME 26.24 −0.87%
Braveheart Bio, Inc. and Zymeworks Inc. are both Biotechnology companies. Braveheart Bio, Inc. and Zymeworks Inc. are of similar size ($1.8B and $1.8B). Braveheart Bio, Inc. has negative trailing earnings, so its P/E is not meaningful; Zymeworks Inc. trades at 39.5×. Zymeworks Inc. has the higher net margin (16.3% vs 0.00%) and the higher return on invested capital (17.5% vs −28.7%). Across the 12 metrics below, Zymeworks Inc. leads on 7 and Braveheart Bio, Inc. on 5.
Valuation
Profitability
| Metric | BRVE | ZYME | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 51.40% | 67.24% |
| Operating margin | 0.00% | 16.60% | 0.00% |
| Net margin | 0.00% | 16.28% | 0.00% |
| Free cash flow margin | 0.00% | (42.42%) | 0.00% |
| Return on equity | 0.00% | 14.98% | (50.28%) |
| Return on assets | 0.00% | 5.50% | (45.89%) |
| Return on invested capital | (28.66%) | 17.49% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack